The knockdown of ADAR1, in conjunction with DNMTi treatment, markedly improves cytokine production, facilitates CD8+ T cell recruitment, and decreases tumor burden in a mouse model of ovarian cancer (236). The gene discussed is CD8A; the disease is neoplasm.